Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

April 7-8, 2017

New York, New York

Scientific Agenda

Friday, April 7, 2017

Session I: Plasma Cell Disorders

Session Chair: Robert Z. Orlowski, MD, PhD

8:00 am

Introduction and pre-activity audience survey

8:15 am

Options for risk stratification and treatment of smoldering myeloma
C. Ola Landgren, MD, PhD

8:35 am

Debate: Induction Therapy
Based on an IMiD and a proteasome inhibitor: Paul G. Richardson, MD
Based on an IMiD and a monoclonal antibody: Ruben Niesvizky, MD

9:05 am

Debate: Use of MRD measurements
Appropriate in standard myeloma care: C. Ola Landgren, MD, PhD
Not yet ready for prime time in standard myeloma care: Paul G. Richardson, MD

9:35 am

Break

9:55 am

Emerging immunotherapies and small molecules for myeloma
Suzanne Lentzsch, MD, PhD

10:15 am

Debate: Post-transplant maintenance
Revlimid alone: Paul G. Richardson, MD
A Revlimid-based combination:Suzanne Lentzsch, MD, PhD

10:45 am

Debate: Salvage therapy
Should be tailored to molecular & clinical risk criteria: Robert Z. Orlowski, MD, PhD
Should be the same for everyone: Ruben Niesvizky, MD

11:15 pm

Final remarks and post-activity learner survey

11:30 am

Lunch

Session II: Chronic Lymphocytic Leukemia

Session Chair: David P. Steensma, MD

1:30 pm

Introduction and pre-activity audience survey

1:45 pm

Debate: Is it appropriate to treat patients with CLL earlier in the era of novel agents?
Yes. The availability of well-tolerated novels agents allows for early intervention to reduce morbidity and mortality in CLL: Matthew S. Davids, MD, MMSc
No. There is no role for early intervention in CLL until an overall survival benefit can be demonstrated: Richard R. Furman, MD

2:15 pm

New approaches to Hairy Cell Leukemia
Jae Park, MD

2:35 pm

Management of adverse events with newer agents for CLL
Timothy G. Call, MD

2:55 pm

Break

Guest Presentation

Session Chair: David P. Steensma, MD

3:15 pm

Updates from Capitol Hill: Healthcare Reform and Cancer Care 2017
Ted Okon, MBA

Session III: Chronic Myeloid Leukemia

Session Chair: David P. Steensma, MD

3:45 pm

CMML: Risk Stratification and Treatment
Mrinal S. Patnaik, MBBS

4:05 pm

Management of AEs with TKIs for CML
Michael J. Mauro, MD

4:25 pm

CML and pregnancy, including partner concerns
Michael J. Mauro, MD

4:45 pm

Final remarks and post-activity audience survey

5:00 pm

Adjourn
 

Saturday, April 8, 2017

Session IV: Not-So-Benign Hematology

Session Chair: David P. Steensma, MD

8:00 am

Welcome and pre-activity audience survey

8:15 am

Anticoagulation in the thrombocytopenic patient
Kenneth A. Bauer, MD

8:35 am

Management of iron deficiency anemia in 2017
Michael Auerbach, MD

8:55 am

Diagnosis and management of PNH in 2017
Carlos Manuel de Castro, MD

Session V: Acute Leukemia

Session Chair: David P. Steensma, MD

9:15 am

New antibodies for ALL
Daniel J. DeAngelo, MD, PhD

9:35 am

Break

Session VI: MPNs and MDS

Session Chair: David P. Steensma, MD

9:55 am

What can be done when ruxolitinib fails in myelofibrosis?
Ruben A. Mesa, MD

10:15 am

Management of Mast Cell Disorders
Clem Akin, MD, PhD

10:35 am

Debate: Molecular genetic testing should be routinely performed in cases of older persons with cytopenias/possible MDS
Yes: Rafael Bejar, MD PhD
No: Gail J. Roboz, MD

11:05 am

How should molecular testing inform transplant decisions in MDS or MPN?
Amer Zeidan, MBBS, MHS

11:25 am

Final remarks and post-activity audience survey

11:40 am

Lunch

Session VII: Lymphomas

Session Chair: John P. Leonard, MD

1:40 pm

Welcome and pre-activity audience survey

1:50 pm

Debate: What is the best second line approach (pre-transplant) for relapsed Hodgkin lymphoma patients  
Chemotherapy alone: Nancy L. Bartlett, MD
Brentuximab alone or with chemotherapy:Ann S. LaCasce, MD, MMSc

2:20 pm

Debate: Is Maintenance Therapy of value following frontline treatment for advanced DLBCL
Yes: Andrew D. Zelentz, MD, PhD
No: Thomas Habermann, MD

2:50 pm

Lecture: What is a Deauville score and how should we use it in employing PET imaging for our lymphoma patients?
Craig H. Moskowitz, MD

3:10 pm

Break

3:30 pm

Debate: What is the most appropriate initial treatment for a 60 year old with mantle cell lymphoma?
Non-intensive strategies: Peter Martin, MD
Transplant-based strategies: Timothy Fenske, MD

4:00 pm

Who will receive CAR-T cell therapy in B-Cell lymphoma in the near future?
Jeremy Abramson, MD

4:20 pm

Debate: What is the best upfront therapeutic approach for advanced follicular lymphoma?
Obinutuzumab-based therapy: Jonathan Friedberg, MD
Rituximab-based therapy: John P. Leonard, MD

4:50 pm

Final remarks and post-activity audience survey

5:00 pm

Adjourn